[go: up one dir, main page]

IL152079A0 - Combination of at least two compounds selected from an at1-receptorantagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups - Google Patents

Combination of at least two compounds selected from an at1-receptorantagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups

Info

Publication number
IL152079A0
IL152079A0 IL15207901A IL15207901A IL152079A0 IL 152079 A0 IL152079 A0 IL 152079A0 IL 15207901 A IL15207901 A IL 15207901A IL 15207901 A IL15207901 A IL 15207901A IL 152079 A0 IL152079 A0 IL 152079A0
Authority
IL
Israel
Prior art keywords
receptorantagonist
hmg
combination
compounds selected
inhibitor
Prior art date
Application number
IL15207901A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL152079A0 publication Critical patent/IL152079A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL15207901A 2000-04-12 2001-04-10 Combination of at least two compounds selected from an at1-receptorantagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups IL152079A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19674300P 2000-04-12 2000-04-12
PCT/EP2001/004115 WO2001076573A2 (en) 2000-04-12 2001-04-10 Combination of at least two compounds selected from an at1-receptor antagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups

Publications (1)

Publication Number Publication Date
IL152079A0 true IL152079A0 (en) 2003-05-29

Family

ID=22726659

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15207901A IL152079A0 (en) 2000-04-12 2001-04-10 Combination of at least two compounds selected from an at1-receptorantagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups

Country Status (20)

Country Link
US (2) US20040023840A1 (xx)
EP (1) EP1326604A2 (xx)
JP (1) JP2003530342A (xx)
KR (1) KR20020089433A (xx)
CN (2) CN1440283A (xx)
AR (1) AR032152A1 (xx)
AU (1) AU2001258323A1 (xx)
BR (1) BR0109966A (xx)
CA (1) CA2405793A1 (xx)
CZ (1) CZ20023381A3 (xx)
HU (1) HUP0400475A3 (xx)
IL (1) IL152079A0 (xx)
MX (1) MXPA02010090A (xx)
NO (1) NO20024921L (xx)
PE (1) PE20020229A1 (xx)
PL (1) PL365696A1 (xx)
RU (1) RU2298418C2 (xx)
SK (1) SK14642002A3 (xx)
WO (1) WO2001076573A2 (xx)
ZA (1) ZA200208203B (xx)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7649100A (en) 1999-08-30 2001-03-26 Aventis Pharma Deutschland Gmbh Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
US6242003B1 (en) * 2000-04-13 2001-06-05 Novartis Ag Organic compounds
SG162605A1 (en) * 2000-06-22 2010-07-29 Novartis Ag Pharmaceutical compositions
US20060127474A1 (en) 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
PT1386608E (pt) * 2001-04-19 2011-07-26 Kowa Co Agente terapêutico para doença glomerular
CA2464561A1 (en) * 2001-10-25 2003-05-01 Depomed, Inc. Methods of treatment using a gastric retained losartan dosage
CA2467095A1 (en) * 2001-11-23 2003-05-30 Solvay Pharmaceuticals Gmbh Hypertonia treatment during the acute phase of a cerebrovascular accident
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
WO2004060399A1 (ja) * 2002-12-27 2004-07-22 Takeda Pharmaceutical Company Limited 体重増加抑制剤
AU2004205642C1 (en) 2003-01-14 2012-01-12 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
DE10335027A1 (de) * 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
JP2006515877A (ja) * 2003-01-16 2006-06-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 心臓血管、心肺、肺又は腎疾患の予防又は治療のための医薬併用剤
DE10301371A1 (de) * 2003-01-16 2004-08-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Kombination zur Prophylaxe oder Therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen Krankheiten
EP1621210B1 (en) * 2003-04-28 2013-06-19 Daiichi Sankyo Company, Limited Adiponectin production enhancer
CA2524175C (en) 2003-04-28 2016-06-14 Sankyo Company Limited Sugar intake-ability enhancer
WO2005007658A2 (en) 2003-07-14 2005-01-27 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
AU2008201290B2 (en) * 2003-09-26 2010-12-09 Astrazeneca Uk Limited Therapeutic treatment
GB0322552D0 (en) * 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
MY147202A (en) * 2003-11-26 2012-11-14 Novartis Ag Compositions comprising organic compounds
EP1699452A2 (en) * 2003-12-16 2006-09-13 Novartis AG Use of statins for the treatment of metabolic syndrome
ES2282062T1 (es) 2004-06-04 2007-10-16 Teva Pharmaceutical Industries Ltd. Composicion farmaceutica que contiene irbesartan.
KR20070074576A (ko) * 2004-10-29 2007-07-12 코와 가부시키가이샤 사구체 질환 치료제
KR100582347B1 (ko) * 2004-12-30 2006-05-22 한미약품 주식회사 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
US8685952B2 (en) 2006-01-31 2014-04-01 Kowa Co., Ltd. Method for the treatment of diabetes
JP5101306B2 (ja) * 2006-01-31 2012-12-19 興和株式会社 糖尿病治療剤
FR2911279B1 (fr) * 2007-01-11 2009-03-06 Servier Lab Utilisation de l'ivabradine pour l'obtention de medicaments destines au traitement de la dysfonction endotheliale
GB0715628D0 (en) * 2007-08-10 2007-09-19 Generics Uk Ltd Solid valsartan composition
SG188548A1 (en) 2010-09-22 2013-04-30 Arena Pharm Inc Modulators of the gpr119 receptor and the treatment of disorders related thereto
RU2505297C1 (ru) * 2012-11-21 2014-01-27 Общество с ограниченной ответственностью "Научно-производственное объединение "Фарматрон" (НПО "Фарматрон") Средство для медикаментозной коррекции нарушений нитроксидергической системы
WO2014186269A1 (en) * 2013-05-13 2014-11-20 Macro Plastics, Inc. Shipping container and safety catch therefor
BR102013028883A2 (pt) * 2013-11-08 2015-10-06 Hypermarcas S A forma farmacêutica oral para a prevenção de doenças vasculares, comprimido como forma farmacêutica e cápsula gelatinosa como forma farmacêutica
MD4412C1 (ro) * 2014-08-29 2016-11-30 Алёна ДУРНЯ Utilizare a acidului 4-({2-butil-5-[2-carboxi-2-(tiofen-2-ilmetil)et-1-en-1-il] -1H-imidazol-1-il}metil) benzoic pentru ameliorarea elasticităţii vasculare în profilaxia complicaţiilor de geneză hipertensivă
NZ734220A (en) 2015-01-06 2022-01-28 Arena Pharm Inc Methods of treating conditions related to the s1p1 receptor
KR102603199B1 (ko) 2015-06-22 2023-11-16 아레나 파마슈티칼스, 인크. Ｓ1ｐ1 수용체-관련 장애에서의 사용을 위한 (ｒ)-2-(7-(4-시클로펜틸-3-(트리플루오로메틸)벤질옥시)-1,2,3,4-테트라히드로시클로-펜타[ｂ]인돌-3-일)아세트산 (화합물 1)의 결정성 ｌ-아르기닌 염
KR20190116416A (ko) 2017-02-16 2019-10-14 아레나 파마슈티칼스, 인크. 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법
EA034975B1 (ru) * 2018-03-13 2020-04-13 Владимир Александрович Горшков-Кантакузен Способ лечения лабильной и пароксизмальной гипертензии
BR112020024762A2 (pt) 2018-06-06 2021-03-23 Arena Pharmaceuticals, Inc. métodos de tratamento de condições relacionadas ao receptor s1p1

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981470A (en) * 1994-06-07 1999-11-09 The University Of Birmingham Uterine fibroid treatment
SK133897A3 (en) * 1995-04-07 1998-02-04 Ciba Geigy Ag Combination compositions containing benazepril or benazeprilat and valsartan
AU716519B2 (en) * 1995-06-30 2000-02-24 Laboratoires Merck Sharp & Dohme - Chibret Snc Method of treating renal disease using an ace inhibitor and an A II antagonist
UA49880C2 (uk) * 1996-03-29 2002-10-15 Смітклайн Бічам Корпорейшн Дигідрат ерпоcартану, фармацевтична композиція, спосіб отримання твердої дозованої форми, спосіб блокування рецепторів ангіотензину іі
EP0930076B1 (en) * 1996-07-15 2004-12-01 Sankyo Company Limited Pharmaceutical compositions comprising CS-866 and insulin resistance improving agents and their use for the treatment of arteriosclerosis and xanthoma

Also Published As

Publication number Publication date
HUP0400475A3 (en) 2006-02-28
KR20020089433A (ko) 2002-11-29
CN1651087A (zh) 2005-08-10
WO2001076573A2 (en) 2001-10-18
CN1440283A (zh) 2003-09-03
US20040023840A1 (en) 2004-02-05
US20070105894A1 (en) 2007-05-10
AR032152A1 (es) 2003-10-29
HUP0400475A2 (hu) 2004-06-28
CA2405793A1 (en) 2001-10-18
CZ20023381A3 (cs) 2003-02-12
NO20024921D0 (no) 2002-10-11
RU2298418C2 (ru) 2007-05-10
PL365696A1 (en) 2005-01-10
WO2001076573A3 (en) 2003-04-17
NO20024921L (no) 2002-11-07
BR0109966A (pt) 2003-08-05
PE20020229A1 (es) 2002-04-11
ZA200208203B (en) 2003-11-07
SK14642002A3 (sk) 2003-05-02
EP1326604A2 (en) 2003-07-16
AU2001258323A1 (en) 2001-10-23
MXPA02010090A (es) 2003-02-12
JP2003530342A (ja) 2003-10-14

Similar Documents

Publication Publication Date Title
IL152079A0 (en) Combination of at least two compounds selected from an at1-receptorantagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups
PT2270005E (pt) Pró-fármaco de um inibidor de ice
EP1194152A4 (en) SIN KINASE INHIBITOR COMPOUNDS
EP1206260A4 (en) SRC-KINASE INHIBITING COMPOUNDS
IL147870A0 (en) Pharmaceutical compositions comprising a hmg reductase inhibitor
HK1061030A1 (en) Rho-kinase inhibitors
HK1061029A1 (en) Rho-kinase inhibitors
IL146288A0 (en) Vla-4 inhibitor compounds
PL359556A1 (en) Method - use of cox-2 inhibitors for preventing immunodeficiency
EP1390052A4 (en) INHIBITION OF JUN KINASE
HK1080911A1 (en) Rust inhibitor
AU2002310798A1 (en) Pharmaceutical compositions comprising a hmg-coa reductase inhibitor
IL145772A0 (en) Prodrugs of thrombin inhibitors
PL355958A1 (en) Application of statins for inhibiting formation of osteoclasts
AU2002306734A1 (en) Inhibitors of plasmepsins
AU2002224550A1 (en) Corrosion inhibitors
AUPQ629000A0 (en) Inhibition of fungi
EP1467978A4 (en) "COMPOUNDS THAT CONTAIN VACCINATES DRUG LIPASE, THEIR SYNTHESIS AND USE"
AU2252101A (en) New synthesis of SPLA2 inhibitors
AU2373600A (en) Novel spla2 inhibitors
AU2002213194A1 (en) Fibrinogen plus a non-plasmin-acting fibrinolysis inhibitor for the reduction or prevention of adhesion formation
IL149524A0 (en) HMG-CoA REDUCTASE INHIBITOR EXTENDED RELEASE FORMULATIONS
HRP20050162A2 (en) ?-lactamase inhibitor prodrug
GB2389113B (en) B-secretase inhibitor
HUP0202431A3 (en) Prodrugs of thrombin inhibitors